肝臓癌治療薬の世界市場2019-2023

【英語タイトル】Global Liver Cancer Drugs Market 2019-2023

Technavioが出版した調査資料(IRTNTR30608)・商品コード:IRTNTR30608
・発行会社(調査会社):Technavio
・発行日:2019年1月9日
・ページ数:107
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後24時間以内)
・調査対象地域:グローバル、アジア、北米、ヨーロッパ(EMEA)
・産業分野:医療・バイオ
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥270,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥324,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥432,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
当調査レポートでは、肝臓癌治療薬の世界市場について調査・分析し、市場概要、市場環境、肝臓癌治療薬市場規模、種類別(免疫療法、標的療法)分析、市場動向、競争環境、主要地域別市場規模(北米、ヨーロッパ、アジアなど)、関連企業情報などを含め、以下の構成でお届け致します。
・エグゼクティブサマリー
・調査範囲・調査手法
・肝臓癌治療薬の世界市場概要
・肝臓癌治療薬の世界市場環境
・肝臓癌治療薬の世界市場動向
・肝臓癌治療薬の世界市場規模
・肝臓癌治療薬の世界市場:業界構造分析
・肝臓癌治療薬の世界市場:種類別(免疫療法、標的療法)
・肝臓癌治療薬の世界市場:地域別市場規模・分析
・肝臓癌治療薬の北米市場規模・予測
・肝臓癌治療薬のヨーロッパ・中東・アフリカ市場規模・予測
・肝臓癌治療薬のアジア太平洋市場規模・予測
・肝臓癌治療薬の主要国分析
・肝臓癌治療薬の世界市場:意思決定フレームワーク
・肝臓癌治療薬の世界市場:成長要因、課題
・肝臓癌治療薬の世界市場:競争環境
・肝臓癌治療薬の世界市場:関連企業情報(ベンダー分析)
【レポートの概要】

About this market
Liver cancer is among the leading causes of cancer-related deaths, globally. The increase in incidence of risk factors like hepatitis B and C and underlying cirrhosis will lead to the rise in risk of liver cancer depending on the etiology. The increase in incidence of life-style diseases like fatty liver is a major risk factor for liver cancer. Furthermore, the increase in incidence of new risk factors like diabetes, obesity, and related non-alcoholic fatty liver disease may also be associated with the increase in incidence of liver cancer. The current disease management for liver cancer is the same for all patients with different etiologies. Advances in disease management for the causative factors may reduce the incidence of liver cancer. Technavio’s analysts have predicted that the liver cancer drugs market will register a CAGR of over 10% by 2023.
Market Overview
Advancements in diagnostics methods
Long-term survival requires advanced diagnostic methods, which may detect small tumors that are often present in asymptomatic patients. Elevated levels of the serum marker alfa-fetoprotein are often indicative of the disease when combined with ultrasonography. Liver biopsy is also a diagnostic method used by many professionals. Various serologic markers may help to improve surveillance accuracy. Computed tomography and magnetic resonance imaging are currently used for liver imaging for surveillance. However, they can be used for the diagnosis and staging of liver cancer.
Only curative option is surgical resection and transplantation
The surgery is often associated with high recurrence rate of tumors. Patients with recurrent tumors are evaluated for liver transplantation. However, a major challenge for liver transplantation is the number of insufficient donor livers. Another challenge is that the disease is often diagnosed in the advanced stage when surgery or transplantation may not be feasible.
For the detailed list of factors that will drive and challenge the growth of the liver cancer drugs market during the 2019-2023, view our report.
Competitive Landscape
The market appears to be concentrated and with the presence of few companies. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
• PART 04: PIPELINE ANALYSIS
• Pipeline analysis
PART 05: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 06: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 07: MARKET SEGMENTATION BY TYPE
• Market segmentation by type
• Comparison by type
• Immunotherapy – Market size and forecast 2018-2023
• Targeted therapy – Market size and forecast 2018-2023
• Market opportunity by type
PART 08: CUSTOMER LANDSCAPE
PART 09: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• Americas – Market size and forecast 2018-2023
• EMEA – Market size and forecast 2018-2023
• APAC – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 10: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 11: MARKET TRENDS
• Market trends
PART 12: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 13: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Bayer
• Bristol-Myers Squibb
• Eisai
• Merck
• Ono Pharmaceutical
PART 14: APPENDIX
• Research methodology
• List of abbreviations


Exhibit 01: Years in consideration
Exhibit 02: Global oncology therapeutics market
Exhibit 03: Segments of global oncology therapeutics market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Late-stage pipeline drugs for liver cancer
Exhibit 07: Market definition – Inclusions and exclusions checklist
Exhibit 08: Market size 2018
Exhibit 09: Global market: Size and forecast 2018-2023 ($ billions)
Exhibit 10: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 11: Five forces analysis 2018
Exhibit 12: Five forces analysis 2023
Exhibit 13: Bargaining power of buyers
Exhibit 14: Bargaining power of suppliers
Exhibit 15: Threat of new entrants
Exhibit 16: Threat of substitutes
Exhibit 17: Threat of rivalry
Exhibit 18: Market condition – Five forces 2018
Exhibit 19: Type – Market share 2018-2023 (%)
Exhibit 20: Comparison by type
Exhibit 21: Immunotherapy – Market size and forecast 2018-2023 ($ billions)
Exhibit 22: Immunotherapy – Year-over-year growth 2019-2023 (%)
Exhibit 23: Targeted therapy – Market size and forecast 2018-2023 ($ billions)
Exhibit 24: Targeted therapy – Year-over-year growth 2019-2023 (%)
Exhibit 25: Market opportunity by type
Exhibit 26: Customer landscape
Exhibit 27: Market share by geography 2018-2023 (%)
Exhibit 28: Geographic comparison
Exhibit 29: Americas – Market size and forecast 2018-2023 ($ billions)
Exhibit 30: Americas – Year-over-year growth 2019-2023 (%)
Exhibit 31: EMEA – Market size and forecast 2018-2023 ($ billions)
Exhibit 32: EMEA – Year-over-year growth 2019-2023 (%)
Exhibit 33: APAC – Market size and forecast 2018-2023 ($ billions)
Exhibit 34: APAC – Year-over-year growth 2019-2023 (%)
Exhibit 35: Key leading countries
Exhibit 36: Market opportunity
Exhibit 37: Decision framework
Exhibit 38: Impact of drivers and challenges
Exhibit 39: Vendor landscape
Exhibit 40: Landscape disruption
Exhibit 41: Vendors covered
Exhibit 42: Vendor classification
Exhibit 43: Market positioning of vendors
Exhibit 44: Bayer – Vendor overview
Exhibit 45: Bayer – Business segments
Exhibit 46: Bayer – Organizational developments
Exhibit 47: Bayer – Geographic focus
Exhibit 48: Bayer – Segment focus
Exhibit 49: Bayer – Key offerings
Exhibit 50: Bristol-Myers Squibb – Vendor overview
Exhibit 51: Bristol-Myers Squibb – Business segments
Exhibit 52: Bristol-Myers Squibb – Organizational developments
Exhibit 53: Bristol-Myers Squibb – Geographic focus
Exhibit 54: Bristol-Myers Squibb – Key offerings
Exhibit 55: Eisai – Vendor overview
Exhibit 56: Eisai – Business segments
Exhibit 57: Eisai – Organizational developments
Exhibit 58: Eisai – Geographic focus
Exhibit 59: Eisai – Segment focus
Exhibit 60: Eisai – Key offerings
Exhibit 61: Merck – Vendor overview
Exhibit 62: Merck – Business segments
Exhibit 63: Merck – Organizational developments
Exhibit 64: Merck – Geographic focus
Exhibit 65: Merck – Segment focus
Exhibit 66: Merck – Key offerings
Exhibit 67: Ono Pharmaceutical – Vendor overview
Exhibit 68: Ono Pharmaceutical – Business segments
Exhibit 69: Ono Pharmaceutical – Organizational developments
Exhibit 70: Ono Pharmaceutical – Geographic focus
Exhibit 71: Ono Pharmaceutical – Key offerings
Exhibit 72: Validation techniques employed for market sizing
Exhibit 73: List of abbreviations




【掲載企業】

Bayer、Bristol-Myers Squibb、Eisai、Merck、Ono Pharmaceutical

★調査レポート[肝臓癌治療薬の世界市場2019-2023] (コード:IRTNTR30608)販売に関する免責事項を必ずご確認ください。
★調査レポート[肝臓癌治療薬の世界市場2019-2023]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆